Roivant signals multiple pivotal trial readouts and accelerates brepocitinib Phase III launch in 2026
Source: SeekingAlpha
2026-02-06 15:46:12 ET
More on Roivant Sciences
- Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript
- Roivant Sciences Ltd. 2025 Q3 - Results - Earnings Call Presentation
- Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth
- Pfizer – Roivant tie-up generates positive mid-stage data for lead asset
- Roivant Sciences Q3 2026 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Roivant signals multiple pivotal trial readouts and accelerates brepocitinib Phase III launch in 2026
Roivant Sciences Ltd.
NASDAQ: ROIV
ROIV Trading
-1.71% G/L:
$28.21 Last:
1,155,726 Volume:
$28.87 Open:
ROIV Latest News
March 04, 2026 11:42:41 pm
BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide
March 03, 2026 04:15:00 pm
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
March 03, 2026 04:15:00 pm
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
ROIV Stock Data
$19,574,426,097
449,460,314
0.77%
170
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
